Skip to main content
Top
Published in: Tumor Biology 3/2013

01-06-2013 | Research Article

A systemic assessment of the association between tumor necrosis factor alpha 308 G/A polymorphism and risk of cervical cancer

Authors: Hua-Lian Zhang, Yi-Jie Zhang

Published in: Tumor Biology | Issue 3/2013

Login to get access

Abstract

Tumor necrosis factor alpha (TNF-α) is a multifunctional cytokine which plays an important role in the human immune response against various pathogens, and there may be a relationship between TNF-α 308 G/A polymorphism and cervical cancer risk. We performed a meta-analysis to get a systemic assessment of the association between TNF-α 308 G/A polymorphism and cervical cancer risk. Electronic searches of PubMed, Embase, and Web of Science were performed for all publications on the association between TNF-α 308 G/A polymorphism and cervical cancer risk through October 26, 2012. The pooled odds ratios (ORs) with their 95 % confidence interval (95 % CIs) were calculated to assess the association. Fifteen studies with a total of 3,743 cervical cancer cases and 4,096 controls were finally included into the meta-analysis. Overall, TNF-α 308 G/A polymorphism was significantly associated with increased risk of cervical cancer under three main genetic comparison models (A vs. G, OR 1.20, 95 % CI 1.02–1.42, P = 0.03; AA vs. GG, OR 1.31, 95 % CI 1.00–1.72, P = 0.048; AA vs. GG/GA, OR 1.30, 95 % CI 1.00–1.71, P = 0.05). Subgroup analysis by ethnicity further showed that there was a significant association between TNF-α 308 G/A polymorphism and increased risk of cervical cancer in Asians (AA vs. GG, OR 1.83, 95 % CI 1.05–3.20, P = 0.034; AA vs. GG/GA, OR 1.84, 95 % CI 1.05–3.22, P = 0.032). The meta-analysis suggests that TNF-α 308 G/A polymorphism is associated with increased risk of cervical cancer, and TNF-α 308 G/A mutant allele A is a risk factor of cervical cancer.
Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
go back to reference Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378:1461–84.PubMedCrossRef Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378:1461–84.PubMedCrossRef
3.
go back to reference Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907.PubMedCrossRef Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907.PubMedCrossRef
4.
go back to reference Thomas M, Narayan N, Pim D, Tomaic V, Massimi P, Nagasaka K, et al. Human papillomaviruses, cervical cancer and cell polarity. Oncogene. 2008;27:7018–30.PubMedCrossRef Thomas M, Narayan N, Pim D, Tomaic V, Massimi P, Nagasaka K, et al. Human papillomaviruses, cervical cancer and cell polarity. Oncogene. 2008;27:7018–30.PubMedCrossRef
5.
6.
go back to reference de Freitas AC, Gurgel AP, Chagas BS, Coimbra EC, do Amaral CM. Susceptibility to cervical cancer: an overview. Gynecol Oncol. 2012;126:304–11.PubMedCrossRef de Freitas AC, Gurgel AP, Chagas BS, Coimbra EC, do Amaral CM. Susceptibility to cervical cancer: an overview. Gynecol Oncol. 2012;126:304–11.PubMedCrossRef
7.
go back to reference Drutskaya MS, Efimov GA, Kruglov AA, Kuprash DV, Nedospasov SA. Tumor necrosis factor, lymphotoxin and cancer. IUBMB Life. 2010;62:283–9.PubMedCrossRef Drutskaya MS, Efimov GA, Kruglov AA, Kuprash DV, Nedospasov SA. Tumor necrosis factor, lymphotoxin and cancer. IUBMB Life. 2010;62:283–9.PubMedCrossRef
8.
go back to reference Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119:651–65.PubMedCrossRef Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119:651–65.PubMedCrossRef
9.
10.
go back to reference Aukrust P, Sandberg WJ, Otterdal K, Vinge LE, Gullestad L, Yndestad A, et al. Tumor necrosis factor superfamily molecules in acute coronary syndromes. Ann Med. 2011;43:90–103.PubMedCrossRef Aukrust P, Sandberg WJ, Otterdal K, Vinge LE, Gullestad L, Yndestad A, et al. Tumor necrosis factor superfamily molecules in acute coronary syndromes. Ann Med. 2011;43:90–103.PubMedCrossRef
11.
go back to reference Patel R, Cafardi JM, Patel N, Sami N, Cafardi JA. Tumor necrosis factor biologics beyond psoriasis in dermatology. Expert Opin Biol Ther. 2011;11:1341–59.PubMedCrossRef Patel R, Cafardi JM, Patel N, Sami N, Cafardi JA. Tumor necrosis factor biologics beyond psoriasis in dermatology. Expert Opin Biol Ther. 2011;11:1341–59.PubMedCrossRef
12.
go back to reference Mekinian A, Tamouza R, Pavy S, Gestermann N, Ittah M, Mariette X, et al. Functional study of TNF-alpha promoter polymorphisms: literature review and meta-analysis. Eur Cytokine Netw. 2011;22:88–102.PubMed Mekinian A, Tamouza R, Pavy S, Gestermann N, Ittah M, Mariette X, et al. Functional study of TNF-alpha promoter polymorphisms: literature review and meta-analysis. Eur Cytokine Netw. 2011;22:88–102.PubMed
13.
go back to reference Qidwai T, Khan F. Tumour necrosis factor gene polymorphism and disease prevalence. Scand J Immunol. 2011;74:522–47.PubMedCrossRef Qidwai T, Khan F. Tumour necrosis factor gene polymorphism and disease prevalence. Scand J Immunol. 2011;74:522–47.PubMedCrossRef
14.
go back to reference Wang N, Yin D, Zhang S, Wei H, Wang S, Zhang Y, et al. TNF-alpha rs1800629 polymorphism is not associated with HPV infection or cervical cancer in the Chinese population. PLoS One. 2012;7:e45246.PubMedCrossRef Wang N, Yin D, Zhang S, Wei H, Wang S, Zhang Y, et al. TNF-alpha rs1800629 polymorphism is not associated with HPV infection or cervical cancer in the Chinese population. PLoS One. 2012;7:e45246.PubMedCrossRef
15.
go back to reference Barbisan G, Perez LO, Contreras A, Golijow CD. TNF-alpha and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumour Biol. 2012;33:1549–56.PubMedCrossRef Barbisan G, Perez LO, Contreras A, Golijow CD. TNF-alpha and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumour Biol. 2012;33:1549–56.PubMedCrossRef
16.
go back to reference Badano I, Stietz SM, Schurr TG, Picconi AM, Fekete D, Quintero IM, et al. Analysis of TNFalpha promoter SNPs and the risk of cervical cancer in urban populations of Posadas (Misiones, Argentina). J Clin Virol. 2012;53:54–9.PubMedCrossRef Badano I, Stietz SM, Schurr TG, Picconi AM, Fekete D, Quintero IM, et al. Analysis of TNFalpha promoter SNPs and the risk of cervical cancer in urban populations of Posadas (Misiones, Argentina). J Clin Virol. 2012;53:54–9.PubMedCrossRef
17.
go back to reference Ivansson EL, Juko-Pecirep I, Gyllensten UB. Interaction of immunological genes on chromosome 2q33 and IFNG in susceptibility to cervical cancer. Gynecol Oncol. 2010;116:544–8.PubMedCrossRef Ivansson EL, Juko-Pecirep I, Gyllensten UB. Interaction of immunological genes on chromosome 2q33 and IFNG in susceptibility to cervical cancer. Gynecol Oncol. 2010;116:544–8.PubMedCrossRef
18.
go back to reference Wang SS, Bratti MC, Rodriguez AC, Herrero R, Burk RD, Porras C, et al. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis. 2009;199:20–30.PubMedCrossRef Wang SS, Bratti MC, Rodriguez AC, Herrero R, Burk RD, Porras C, et al. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis. 2009;199:20–30.PubMedCrossRef
19.
go back to reference Kohaar I, Thakur N, Salhan S, Batra S, Singh V, Sharma A, et al. TNFalpha-308 G/A polymorphism as a risk factor for HPV associated cervical cancer in Indian population. Cell Oncol. 2007;29:249–56.PubMed Kohaar I, Thakur N, Salhan S, Batra S, Singh V, Sharma A, et al. TNFalpha-308 G/A polymorphism as a risk factor for HPV associated cervical cancer in Indian population. Cell Oncol. 2007;29:249–56.PubMed
20.
go back to reference Govan VA, Constant D, Hoffman M, Williamson AL. The allelic distribution of -308 tumor necrosis factor-alpha gene polymorphism in south African women with cervical cancer and control women. BMC Cancer. 2006;6:24.PubMedCrossRef Govan VA, Constant D, Hoffman M, Williamson AL. The allelic distribution of -308 tumor necrosis factor-alpha gene polymorphism in south African women with cervical cancer and control women. BMC Cancer. 2006;6:24.PubMedCrossRef
21.
go back to reference Duarte I, Santos A, Sousa H, Catarino R, Pinto D, Matos A, et al. G-308A TNF-alpha polymorphism is associated with an increased risk of invasive cervical cancer. Biochem Biophys Res Commun. 2005;334:588–92.PubMedCrossRef Duarte I, Santos A, Sousa H, Catarino R, Pinto D, Matos A, et al. G-308A TNF-alpha polymorphism is associated with an increased risk of invasive cervical cancer. Biochem Biophys Res Commun. 2005;334:588–92.PubMedCrossRef
22.
go back to reference Stanczuk GA, Sibanda EN, Tswana SA, Bergstrom S. Polymorphism at the -308-promoter position of the tumor necrosis factor-alpha (TNF-alpha) gene and cervical cancer. Int J Gynecol Cancer. 2003;13:148–53.PubMedCrossRef Stanczuk GA, Sibanda EN, Tswana SA, Bergstrom S. Polymorphism at the -308-promoter position of the tumor necrosis factor-alpha (TNF-alpha) gene and cervical cancer. Int J Gynecol Cancer. 2003;13:148–53.PubMedCrossRef
23.
go back to reference Gostout BS, Poland GA, Calhoun ES, Sohni YR, Giuntoli 2nd RL, McGovern RM, et al. TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol Oncol. 2003;88:326–32.PubMedCrossRef Gostout BS, Poland GA, Calhoun ES, Sohni YR, Giuntoli 2nd RL, McGovern RM, et al. TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol Oncol. 2003;88:326–32.PubMedCrossRef
24.
go back to reference Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRef Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRef
25.
go back to reference Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
26.
27.
go back to reference Jang WH, Yang YI, Yea SS, Lee YJ, Chun JH, Kim HI, et al. The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett. 2001;166:41–6.PubMedCrossRef Jang WH, Yang YI, Yea SS, Lee YJ, Chun JH, Kim HI, et al. The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett. 2001;166:41–6.PubMedCrossRef
28.
go back to reference Calhoun ES, McGovern RM, Janney CA, Cerhan JR, Iturria SJ, Smith DI, et al. Host genetic polymorphism analysis in cervical cancer. Clin Chem. 2002;48:1218–24.PubMed Calhoun ES, McGovern RM, Janney CA, Cerhan JR, Iturria SJ, Smith DI, et al. Host genetic polymorphism analysis in cervical cancer. Clin Chem. 2002;48:1218–24.PubMed
29.
go back to reference Deshpande A, Nolan JP, White PS, Valdez YE, Hunt WC, Peyton CL, et al. TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis. 2005;191:969–76.PubMedCrossRef Deshpande A, Nolan JP, White PS, Valdez YE, Hunt WC, Peyton CL, et al. TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis. 2005;191:969–76.PubMedCrossRef
30.
go back to reference Singh H, Jain M, Sachan R, Mittal B. Association of TNFα (-308 G > A) and IL-10 (-819C > T) promoter polymorphisms with risk of cervical cancer. Int J Gynecol Cancer. 2009;19:1190–4.PubMedCrossRef Singh H, Jain M, Sachan R, Mittal B. Association of TNFα (-308 G > A) and IL-10 (-819C > T) promoter polymorphisms with risk of cervical cancer. Int J Gynecol Cancer. 2009;19:1190–4.PubMedCrossRef
31.
go back to reference Wang Q, Zhang C, Walayat S, Chen HW, Wang Y. Association between cytokine gene polymorphisms and cervical cancer in a Chinese population. Eur J Obstet Gynecol Reprod Biol. 2011;158:330–3.PubMedCrossRef Wang Q, Zhang C, Walayat S, Chen HW, Wang Y. Association between cytokine gene polymorphisms and cervical cancer in a Chinese population. Eur J Obstet Gynecol Reprod Biol. 2011;158:330–3.PubMedCrossRef
32.
go back to reference Gorouhi F, Islami F, Bahrami H, Kamangar F. Tumour-necrosis factor-α polymorphisms and gastric cancer risk: a meta-analysis. Br J Cancer. 2008;98:1443–51.PubMedCrossRef Gorouhi F, Islami F, Bahrami H, Kamangar F. Tumour-necrosis factor-α polymorphisms and gastric cancer risk: a meta-analysis. Br J Cancer. 2008;98:1443–51.PubMedCrossRef
33.
go back to reference Fan W, Maoqing W, Wangyang C, Fulan H, Dandan L, Jiaojiao R, et al. Relationship between the polymorphism of tumor necrosis factor-alpha-308 G > A and susceptibility to inflammatory bowel diseases and colorectal cancer: a meta-analysis. Eur J Hum Genet. 2011;19:432–7.PubMedCrossRef Fan W, Maoqing W, Wangyang C, Fulan H, Dandan L, Jiaojiao R, et al. Relationship between the polymorphism of tumor necrosis factor-alpha-308 G > A and susceptibility to inflammatory bowel diseases and colorectal cancer: a meta-analysis. Eur J Hum Genet. 2011;19:432–7.PubMedCrossRef
34.
go back to reference Yang Y, Luo C, Feng R, Bi S. The TNF-alpha, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2011;137:947–52.PubMedCrossRef Yang Y, Luo C, Feng R, Bi S. The TNF-alpha, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2011;137:947–52.PubMedCrossRef
35.
go back to reference Wang J, Cao C, Luo H, Xiong S, Xu Y, Xiong W. Tumour necrosis factor alpha -308 G/A polymorphism and risk of the four most frequent cancers: a meta-analysis. Int J Immunogenet. 2011;38:311–20.PubMedCrossRef Wang J, Cao C, Luo H, Xiong S, Xu Y, Xiong W. Tumour necrosis factor alpha -308 G/A polymorphism and risk of the four most frequent cancers: a meta-analysis. Int J Immunogenet. 2011;38:311–20.PubMedCrossRef
36.
go back to reference Peng WJ, He Q, Yang JX, Wang BX, Lu MM, Wang S, et al. Meta-analysis of association between cytokine gene polymorphisms and lung cancer risk. Mol Biol Rep. 2012;39:5187–94.PubMedCrossRef Peng WJ, He Q, Yang JX, Wang BX, Lu MM, Wang S, et al. Meta-analysis of association between cytokine gene polymorphisms and lung cancer risk. Mol Biol Rep. 2012;39:5187–94.PubMedCrossRef
Metadata
Title
A systemic assessment of the association between tumor necrosis factor alpha 308 G/A polymorphism and risk of cervical cancer
Authors
Hua-Lian Zhang
Yi-Jie Zhang
Publication date
01-06-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0699-x

Other articles of this Issue 3/2013

Tumor Biology 3/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine